LNK01004 is a novel kinase inhibitor that can simultaneously inhibit multiple inflammatory cytokines and block multiple signaling pathways related to psoriasis Lynk Pharmaceuticals, an innovative clinical stage company, has announced that its Class I innovative drug LNK01004, has been approved by National Medical Products Administration (NMPA) for clinical trials for the treatment of psoriasis. LNK01004 is a novel kinase inhibitor that can simultaneously inhibit multiple inflammatory cytokines and block multiple signaling pathways related to psoriasis, and thus potentially offer maximal efficacy. In preclinical studies, LNK01004 showed a skin-restricted drug exposure. The drug is mainly distributed in the site of action
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!